S047 Advanced Therapeutics for Complex Dermatologic Disease
DESCRIPTION
The skin is a window into the inner workings of the immune system and the rest of the body. As dermatologists, we play a critical role in diagnosis and management, but often require the help of other specialties to treat complex disease. In this session, we hope to demystify the systemic therapeutics that are often used in treatment of complex skin disease, and in areas where appropriate, will demonstrate how dermatologists can reclaim the management of systemic disease.
We will also highlight research on new adverse effects for systemic medications, as well as novel treatment paradigms in our specialty.
LEARNING OBJECTIVES
Develop treatment algorithms for complex medical dermatologic conditions, namely: connective tissue diseases, blistering disorders, neutrophilic dermatoses, hidradenitis suppurativa, GVHD, and oncodermatologic conditions
Manage complications that may arise as a result of systemic therapeutic options prescribed by the dermatologist
Discuss our new understanding of pathophysiologic mechanisms that may impact adverse effects and open new treatment paradigms
SCHEDULE
1:00 PM
Welcome and Introduction to the Session
Steven T. Chen, MD, MPH, FAAD
1:05 PM
Skin Toxicity Management Pearls in Oncodermatology: More than Skin Deep
Lauren Marie Guggina, MD, FAAD
1:30 PM
When the Cure Becomes the Disease: Treating Graft-vs-Host Disease
Michael Stephens, MD, FAAD
1:55 PM
Rheum for Improvement: Update in Treatments for Connective Tissue Diseases
Scott Elman, MD, FAAD
2:20 PM
Exploring New Frontiers in the Treatment of Hidradenitis Suppurativa
Madeline DeWane, MD, FAAD
2:45 PM
Pearls from the Inpatient Wards: Management of Severe Cutaneous Adverse Reactions
Chun-Bing Chen, MD, IFAAD
3:10 PM
Itching for an Update on the Treatment of Pruritus
Sarina Elmariah, MD, FAAD
3:35 PM
Update on the Treatment of Immune Related Adverse Events from Checkpoint Inhibition
Steven T. Chen, MD, MPH, FAAD
DIRECTOR
Steven T. Chen, MD, MPH, FAAD
SPEAKERS
Chun-Bing Chen, MD, IFAAD
Madeline DeWane, MD, FAAD
Scott Elman, MD, FAAD
Sarina Elmariah, MD, FAAD
Lauren Marie Guggina, MD, FAAD
Michael Stephens, MD, FAAD
DISCLOSURES
Chun-Bing Chen, MD, IFAAD
No financial relationships exist with ineligible companies.
Steven T. Chen, MD, MPH, FAAD
AbbVie – Advisory Board(Honoraria); Vertex Pharmaceuticals Incorporated – Employee (w-2 relationship)(Salary); VisualDx – Independent Contractor(Fees);
Madeline DeWane, MD, FAAD
VeraDermics Inc. – Founder(No Compensation Received);
Scott Elman, MD, FAAD
Biogen – Consultant(Fees); Blueprint Medicines – Advisory Board(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);
Sarina Elmariah, MD, FAAD
Eli Lilly – Other(Honoraria); Galderma Laboratories, LP – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria);
Lauren Marie Guggina, MD, FAAD
No financial relationships exist with ineligible companies.
Michael Stephens, MD, FAAD
No financial relationships exist with ineligible companies.